Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with significant public health concerns. This review examines the landscape of KRAS inhibition in colorectal cancer (CRC), focusing on recent advances in therapeutic strategies targeting this oncogene. Historically deemed undruggable due to its complex structure and essential role in tumorigenesis,KRASmutations are prevalent in CRC and are associated with poor prognosis. However, breakthroughs in drug development have led to the emergence of KRAS inhibitors as promising treatment options. This review discusses various classes of KRAS inhibitors, including covalent and non-covalent inhibitors, as well as combination therapies aimed at enhancing efficacy and overcoming resistance mechanisms. It highlights recent clinical trials evaluating the efficacy of KRAS inhibitors either as monotherapy or in combination with other agents, such as anti-EGFR antibodies. Despite challenges such as resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment and holds promise for improving patient outcomes in the future.
结直肠癌（CRC）作为全球癌症相关死亡的主要原因之一，已成为重大公共卫生问题。本文综述了KRAS抑制在结直肠癌领域的研究进展，重点关注针对该致癌基因治疗策略的最新突破。KRAS突变因其复杂的结构和在肿瘤发生中的关键作用，长期以来被视为不可成药靶点，其在结直肠癌中普遍存在且与不良预后相关。然而，药物研发领域的突破性进展使KRAS抑制剂成为极具前景的治疗选择。本综述系统探讨了各类KRAS抑制剂，包括共价与非共价抑制剂，以及旨在增强疗效、克服耐药机制的联合治疗方案。重点分析了近期评估KRAS抑制剂单药或联合用药（如抗EGFR抗体）疗效的临床试验。尽管面临耐药机制和肿瘤异质性等挑战，KRAS抑制剂的研发仍标志着结直肠癌治疗领域的重大进步，为未来改善患者预后带来新的希望。
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
肿瘤(癌症)患者之家